<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>College of Medical, Veterinary &amp;Life Sci</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/90051600-6EF2-4093-BA8C-2B4B6F550895"><gtr:id>90051600-6EF2-4093-BA8C-2B4B6F550895</gtr:id><gtr:name>University of Dundee</gtr:name><gtr:address><gtr:line1>University of Dundee</gtr:line1><gtr:line2>Nethergate</gtr:line2><gtr:postCode>DD1 4HN</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4FD2374A-BD17-4E10-AC50-297E1AABFD28"><gtr:id>4FD2374A-BD17-4E10-AC50-297E1AABFD28</gtr:id><gtr:firstName>Malcolm</gtr:firstName><gtr:surname>Walkinshaw</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F76750E6-D3E0-49FE-AF75-EEDEE61210D9"><gtr:id>F76750E6-D3E0-49FE-AF75-EEDEE61210D9</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:surname>Croft</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/77754C4E-2FAD-4B3F-906F-1A7E470D075E"><gtr:id>77754C4E-2FAD-4B3F-906F-1A7E470D075E</gtr:id><gtr:firstName>Nicholas</gtr:firstName><gtr:surname>Turner</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/710CAA6C-1D81-41EE-8673-58099B2B7FF3"><gtr:id>710CAA6C-1D81-41EE-8673-58099B2B7FF3</gtr:id><gtr:firstName>Jeremy</gtr:firstName><gtr:otherNames>Charles</gtr:otherNames><gtr:surname>Mottram</gtr:surname><gtr:orcidId>0000-0001-5574-3766</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/50E2265C-4DD4-418E-8199-453207C32A97"><gtr:id>50E2265C-4DD4-418E-8199-453207C32A97</gtr:id><gtr:firstName>Karen</gtr:firstName><gtr:otherNames>Margaret</gtr:otherNames><gtr:surname>Grant</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/877AF669-9449-4215-958D-89F3C2A38B87"><gtr:id>877AF669-9449-4215-958D-89F3C2A38B87</gtr:id><gtr:firstName>Peter</gtr:firstName><gtr:otherNames>Martin</gtr:otherNames><gtr:surname>Fischer</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0400028"><gtr:id>738B8860-5FE8-45FA-A1D6-2FFE9A6EC52D</gtr:id><gtr:title>CDK inhibitors as drugs for trypanosomatid parasitic protozoa</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0400028</gtr:grantReference><gtr:abstractText>The leishmaniases and trypanosomiasis (sleeping sickness) are predominantly diseases of the developing world. 350 million people are at risk of infection with leishmaniasis in 88 countries worldwide and sleeping sickness threatens over 60 million people in 36 countries of sub-Saharan Africa. Within affected countries, the diseases are most prevalent amongst the most impoverished. Existing treatments are inadequate: the most commonly used treatments cannot be taken orally, they cause unpleasant, and sometimes life-threatening, side effects and increasingly are ineffective due to drug resistance. Through our work on the parasites that cause these diseases, we have identified a protein, CRK3, which regulates the parasite?s ability to replicate and is essential for its survival. We want to utilise the expertise of a small drug discovery company, Cyclacel to find compounds that are more potent and specific for the parasite protein. These compounds, which are similar to some of those in development for cancer, will then be tested to determine whether they could be developed as drugs for the treatment of leishmaniasis and trypanosomiasis.</gtr:abstractText><gtr:technicalSummary>Cyclin-dependent kinases (CDKs) are key regulators of the eukaryote cell cycle and validated targets for anti-cancer drug design. We shall piggy-back proprietary technologies developed by a biopharmaceutical company, Cyclacel, to develop CDK inhibitors specific for Leishmania ssp and Trypanosoma brucei. Our target is the CRK3 protein kinase, which has been shown to be essential for parasite proliferation. We shall identify novel families of CRK3 inhibitors by database mining, in silico screening and high throughput screening of a proprietary small molecule library. Lead compounds will be refined by synthetic chemistry and combinatorial chemistry on the basis of 3D modeling and X-ray crystal analysis. Compounds will be tested in vitro and in vivo against the parasites. The project aims to shorten the drug discovery process by exploiting Cyclacel?s expertise in taking mammalian CDK inhibitors to phase II clinical trials and to utilize pharmacokinetic and pharmacodynamic data derived from the anticancer projects. The objective is to identify a lead compound(s) against CRK3 within 3 years that can then progress to full drug development.</gtr:technicalSummary><gtr:fund><gtr:end>2009-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-09-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>695328</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Dundee</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Biological Chemistry and Drug Discovery (BCDD)</gtr:department><gtr:description>Dundee Drug Discovery Unit</gtr:description><gtr:id>EA02F83E-7508-469A-9950-B7336B8E4F94</gtr:id><gtr:impact>Two papers have been submitted for publication</gtr:impact><gtr:outcomeId>5BA09B3043E-1</gtr:outcomeId><gtr:partnerContribution>Inhibitors of CRK3:CYC6 protein kinase</gtr:partnerContribution><gtr:piContribution>Provision of recombinant CRK3:CYC6 protein kinase for high throughput screening for chemical inhibitors</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>F2311AD1-530B-4452-9ADB-708A8BF3244A</gtr:id><gtr:title>Anti-leishmanial activity of disubstituted purines and related pyrazolo[4,3-d]pyrimidines.</gtr:title><gtr:parentPublicationTitle>Bioorganic &amp; medicinal chemistry letters</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/650c6e0d6fbe422f1bd560e2aa6de249"><gtr:id>650c6e0d6fbe422f1bd560e2aa6de249</gtr:id><gtr:otherNames>Jorda R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0960-894X</gtr:issn><gtr:outcomeId>VfaGU2QGhZ3</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C1A88AF9-6579-42F8-90E5-F7D7B7E264A7</gtr:id><gtr:title>Recombinant Leishmania mexicana CRK3:CYCA has protein kinase activity in the absence of phosphorylation on the T-loop residue Thr178.</gtr:title><gtr:parentPublicationTitle>Molecular and biochemical parasitology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8211ac2d6c551d0eb0fd34b37c5b95b"><gtr:id>b8211ac2d6c551d0eb0fd34b37c5b95b</gtr:id><gtr:otherNames>Gomes FC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0166-6851</gtr:issn><gtr:outcomeId>c8LT9BmpKEc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8FC822D9-583E-4574-A88E-02757823D046</gtr:id><gtr:title>Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3.</gtr:title><gtr:parentPublicationTitle>ChemMedChem</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8963cf89b879a7ff9f878534cc7a6f3"><gtr:id>b8963cf89b879a7ff9f878534cc7a6f3</gtr:id><gtr:otherNames>Cleghorn LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1860-7179</gtr:issn><gtr:outcomeId>igvzHbGUx2F</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>99374DF5-5C87-48D7-97DA-76C4D2BDBBDE</gtr:id><gtr:title>Identification of lead compounds targeting the cathepsin B-like enzyme of Eimeria tenella.</gtr:title><gtr:parentPublicationTitle>Antimicrobial agents and chemotherapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9e7915410f8784e7ac8ba8d6cbe54848"><gtr:id>9e7915410f8784e7ac8ba8d6cbe54848</gtr:id><gtr:otherNames>Schaeffer M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0066-4804</gtr:issn><gtr:outcomeId>pm_14580_20_22143531</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F60669DC-74F9-4296-9DED-E55C0641A46F</gtr:id><gtr:title>High throughput screens yield small molecule inhibitors of Leishmania CRK3:CYC6 cyclin-dependent kinase.</gtr:title><gtr:parentPublicationTitle>PLoS neglected tropical diseases</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d5ba213a96da4cc6d3db0bfa2f8a0989"><gtr:id>d5ba213a96da4cc6d3db0bfa2f8a0989</gtr:id><gtr:otherNames>Walker RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1935-2727</gtr:issn><gtr:outcomeId>A15553D9_5A15553D9_5</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0400028</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>03BA7BC9-C251-48FC-8EA9-5F7414A63FEE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Infection</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>